Bellevue Group AG Purchases Shares of 193,125 Auris Medical Holding AG (EARS)  Stephan Jacobs | Aug 17th, 2018
Bellevue Group AG purchased a new position in shares of Auris Medical Holding AG (NASDAQ:EARS) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 193,125 shares of the biotechnology company's stock, valued at approximately $151,000.
Separately, Sofinnova Ventures Inc bought a new stake in shares of Auris Medical during the first quarter worth approximately $1,251,000. Hedge funds and other institutional investors own 26.31% of the company's stock. Get Auris Medical alerts:
EARS opened at $0.24 on Friday. The company has a quick ratio of 1.40, a current ratio of 1.40 and a debt-to-equity ratio of -3.12. Auris Medical Holding AG has a fifty-two week low of $0.23 and a fifty-two week high of $9.50.
Auris Medical (NASDAQ:EARS) last posted its quarterly earnings results on Tuesday, May 15th. The biotechnology company reported ($0.32) earnings per share for the quarter.
Separately, ValuEngine raised shares of Auris Medical from a "sell" rating to a "hold" rating in a research note on Wednesday, May 2nd.
About Auris Medical
Auris Medical Holding AG, a clinical-stage biopharmaceutical company, focuses on the development of novel products for the treatment of inner ear disorders. Its product candidates include AM-101, which is in phase III clinical development for the treatment of acute inner ear tinnitus; and AM-111 that is in phase III clinical development for the treatment of acute inner ear hearing loss.
Featured Story: Closed-End Mutual Funds
Want to see what other hedge funds are holding EARS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Auris Medical Holding AG (NASDAQ:EARS). Receive News & Ratings for Auris Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Auris Medical and related companies with MarketBeat.com's FREE daily email newsletter . Ã‚